Indications |
Nasal Nasal congestion Adult: As 0.05% solution: Spray 1-3 times into each nostril bid. Child: ≥6 yr: Instill or spray 0.05% solution 1-3 times into each nostril bid. Ophthalmic Conjunctival decongestant Adult: Instil 1-2 drops of 0.025% solution into the eye(s) 6 hrly when necessary. Child: ≥6 yr: Instill 1-2 drops of 0.025% solution into the eye(s) 6 hrly when necessary. |
Contraindications |
Glaucoma; hyperthyroidism, heart disease (including angina), hypertension, advanced arteriosclerotic conditions. Children <6 yr. |
Warnings / Precautions |
Pregnancy, lactation. Difficulty in urination secondary to prostate enlargement; DM. |
Adverse Reactions |
Nasal drops or spray: Local stinging or burning, sneezing, dryness of mouth and throat. Prolonged or frequent use may cause rebound congestion. Headache, insomnia, tachycardia, hypertension, nervousness, nausea, dizziness, palpitation, arrhythmia. Eye drops: Dryness of eye. |
Drug Interactions |
Potentially Fatal: Hypertensive crisis with MAOIs. See Below for More oxymetazoline Drug Interactions |
Mechanism of Actions |
Oxymetazoline is a direct-acting sympathomimetic which has vasoconstrictor effect on mucosal blood vessels when applied topically and in turn reduces oedema of the nasal mucosa. Duration: Up to 12 hr. |
ATC Classification |
R01AA05 - oxymetazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants. R01AB07 - oxymetazoline ; Belongs to the class of topical sympathomimetic combination preparations, excluding corticosteroids. Used as nasal decongestants. S01GA04 - oxymetazoline ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants. |
Available As |
|
Oxymetazoline
Post Review about Oxymetazoline Click here to cancel reply.
Oxymetazoline Containing Brands
Oxymetazoline is used in following diseases
Drug - Drug Interactions of Oxymetazoline
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.